BioInvent Q1’21: In a Good Position
Research Note
2021-04-30
07:20
Redeye believes the progress in Q1 has strengthened BioInvent’s position further ahead of the crucial clinical inflection point for the lead candidate BI-1206 later this year.
NE
Niklas Elmhammer
Disclosures and disclaimers